A Securities and Exchange Commission plan to let public companies cut quarterly disclosures to twice a year moved closer to reality after passing a White House review.
At 55, owners are often in a stronger position to adapt, lead change, shape the firm’s future and participate in a transition from a position of strength.
Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year.